For example, an Impact of anti-hyperglyceMic Agents on NAFLD proGressIoN in type 2 Diabetes (IMAGIN) study on 63 T2DM patients shows that those patients receiving combined “metformin + empagliflozin” therapy (compared to metformin alone) possess lower BMI (body mass index), glycated hemoglobin, ALT (alanine transaminase), CAP (controlled attenuation parameter), and steatosis degree [33]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.